Cargando…

Frontline therapy for newly diagnosed patients with multiple myeloma

Since the introduction of an alkylator to the treatment of multiple myeloma (MM), new effective agents have been developed, such as immunomodulatory drugs including thalidomide, lenalidomide, and pomalidomide; proteasome inhibitors including bortezomib, carfilzomib, and ixazomib; monoclonal antibodi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Sung-Hoon, Jo, Jae-Cheol, Song, Ga-Young, Ahn, Seo-Yeon, Yang, Deok-Hwan, Ahn, Jae-Sook, Kim, Hyeoung-Joon, Lee, Je-Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386893/ https://www.ncbi.nlm.nih.gov/pubmed/32719175 http://dx.doi.org/10.5045/br.2020.S007

Ejemplares similares

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2019)

The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2014)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
por: Jung, Sung-Hoon, et al.
Publicado: (2015)

Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma
por: Chu, Tan-Huy, et al.
Publicado: (2022)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2020)

P1194: PROGNOSTIC SIGNIFICANCE OF SEQUENTIAL 18F-FDG PET/CT DURING THE TREATMENT OF ANTHRACYCLINE-CONTAINING FRONTLINE CHEMOTHERAPY IN PERIPHERAL T CELL LYMPHOMAS
por: Song, Ga-Young, et al.
Publicado: (2023)

Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2013)

Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
por: Thangaraj, Jaya Lakshmi, et al.
Publicado: (2022)

Newly Developed Multiple Myeloma in a Patient with Primary T-Cell Lymphoma of Bone
por: Hwang, Jun-Eul, et al.
Publicado: (2008)

Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma
por: Kim, Mihee, et al.
Publicado: (2021)

Next‐generation sequencing‐based analysis to assess the pattern of relapse in patients with Philadelphia‐positive acute lymphoblastic leukemia
por: Ahn, Jae‐Sook, et al.
Publicado: (2022)

Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma
por: Yang, Deok-Hwan, et al.
Publicado: (2015)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
por: Hoang, My-Dung, et al.
Publicado: (2015)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)
por: Kim, Therasa, et al.
Publicado: (2018)

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
por: Jung, Sung-Hoon, et al.
Publicado: (2016)

Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
por: Jung, Sung-Hoon, et al.
Publicado: (2012)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation
por: Lee, Seung-Shin, et al.
Publicado: (2015)

A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
por: Kim, Mihee, et al.
Publicado: (2023)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia
por: Ahn, Seo-Yeon, et al.
Publicado: (2023)

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant
por: Ailawadhi, Sikander, et al.
Publicado: (2022)

Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma
por: Park, Hyung Chul, et al.
Publicado: (2013)

Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and (18)F-FDG PET/CT
por: Cho, Hee Jeong, et al.
Publicado: (2021)

Cellular immunotherapy using dendritic cells against multiple myeloma
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
por: Fonseca, Rafael, et al.
Publicado: (2020)

A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment
por: Bae, Soo-Young, et al.
Publicado: (2011)

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
por: Ahn, Jae-Sook, et al.
Publicado: (2011)

Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment
por: Nguyen, Hong Hanh, et al.
Publicado: (2016)

FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
por: Ahn, Jae-Sook, et al.
Publicado: (2022)

A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
por: Chang, Hye Jung, et al.
Publicado: (2011)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
por: Tran, Huong Thi Thanh, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_co64n98do3klehnaerfv246gt2